MarketsReportedMedium

AstraZeneca, Merck deals lift Chinese biotech as US curbs fears ease

AstraZeneca's $2B equity investment in Summit Therapeutics to advance Akeso's ivonescimab, plus a new Merck deal, signal sustained global interest in Chinese biotech. This follows easing fears of US restrictions on Chinese biotech, boosting sector sentiment. The deals underscore China's growing role in innovative drug development and may attract further foreign investment.

South China Morning Postabout 18 hours agoCN, US, GBengCredibility 27%View source

Score Breakdown

Mosaic Score5.7

Model confidence0.9

Significance0.5

Source credibility0.3

Intelligence Tags

#biotech #pharma #mergers-acquisitions #china #astrazeneca #merck

Locations

Florida

Entities

countrycountrycountry

Source

Part of 2 situations

activeGeopoliticsMarkets16h ago

China — 106 developments

→ stable·29 signals·CN, US, JP +7Score 5.2

developingMarkets17h ago

AstraZeneca Invests $2B in Summit Therapeutics for Ivonescimab Development

AstraZeneca has confirmed a $2 billion equity investment in Summit Therapeutics to accelerate the development of ivonescimab, a bispecific antibody, for cancer treatment. This strategic move aims to combine ivonescimab with antibody-drug conjugates across multiple tumor types, signaling a significant bet on next-generation cancer immunotherapy. The deal also highlights sustained global interest in Chinese biotech, specifically Akeso's ivonescimab, amidst easing fears of US restrictions.

→ stable·↑2 signals·GB, US, CNScore 4.9